10489-74-4

Basic information

• Product Name: ETHYL-2-OXIMINOOXAMATE, 97%
• Synonyms: Ethyl 2-Amino(hydroxyimino)acetate;Ethyl amino(hydroxyimino)ethanoate;Acetic acid, 2-(hydroxyaMino)-2-iMino-, ethyl ester;(Ethoxycarbonyl)formamide oxime;Ethoxycarbonyl formamidoxime;Ethyl 2-(hydroxyamino)-2-iminoacetate;Ethyl 2-(hydroxyimino)-2-aminoacetate;Ethyl 2-amino-2-(hydroxyimino)acetate
• CAS NO: 10489-74-4
• Molecular Formula: C₄H₈N₂O₃
• Molecular Weight: 132.118
• EINECS: 200-258-5
• Product Categories: C2 to C5;Carbonyl Compounds;Esters
• Mol File: 10489-74-4.mol
• Article Data: 12

Chemical Properties

• Melting Point: 99-103 °C(lit.)
• Boiling Point: 198℃
• Flash Point: 74℃
• Appearance: White to yellow/Crystalline Powder
• Density: 1.34
• Vapor Pressure: 0.00156mmHg at 25°C
• Refractive Index: 1.498
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.27±0.69(Predicted)
• CAS DataBase Reference: ETHYL-2-OXIMINOOXAMATE, 97%(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL-2-OXIMINOOXAMATE, 97%(10489-74-4)
• EPA Substance Registry System: ETHYL-2-OXIMINOOXAMATE, 97%(10489-74-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 10489-74-4(Hazardous Substances Data)

Usage

Uses

Ethyl 2-Amino(hydroxyimino)acetate is an intermediate used in the synthesis of N-(2-Hydroxyethyl)-5-methyl-1,2,4-oxadiazole-3-carboxamide (H942278), which is a photolysis product of Metronidazole (M338880), an antibiotic.

InChI:InChI=1/C4H8N2O3/c1-2-9-4(7)3(5)6-8/h8H,2H2,1H3,(H2,5,6)

Upstream product

• 623-49-4 ethyl cyanoformate 
• 51216-90-1 ethyl 2-thiooxamate 
• 95080-93-6 ethyl chlorooximidoacetate 

Downstream Products

• 1233531-44-6 ethyl 2-(hydroxyimino)-2-(5-methyl-2-nitrobenzamido)acetate 
• 1081533-58-5 C₁₁H₁₂N₂O₄ 
• 1426573-01-4 ethyl 5-((2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octan-2-yl)-1,2,4-oxadiazole-3-carboxylate 
• 1258517-58-6 (Z)-ethyl 2-amino-2-(2-(2,5-difluorophenyl)acetoxyimino)acetate 
• 42526-30-7 ethyl 5-oxo-4,5-dihydro-1,2,4-oxadiazole-3-carboxylate 
• 1009620-97-6 ethyl 5-(chloromethyl)-1,2,4-oxadiazole-3-carboxylate 
• 955372-52-8 5-[3-(2-fluoro-4-iodo-phenylamino)-pyridin-4-yl]-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester 
• 917608-63-0 ethyl 5-(2'-deoxy-3',5'-di-O-p-toluoyl-β-D-erythro-pentofuranosyl)-1,2,4-oxadiazole-3-carboxylate 
• 39512-59-9 ethyl 1,2,4-oxadiazole-3-carboxylate 

Relevant articles and documents

CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE

Provided are compounds of Formula (I): Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, A1, B1, B2, Q1 and Q2 are as defined herein; and methods for their use and production.

IMIDAZOLE-BASED COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

Imidazole-based compounds as hepatitis C virus (HCV) inhibitors. The compounds have an imidazole core that is disubstituted via amide links. Also described are a pharmaceutical composition incorporating the imidazole-based compound, a method of preparing these compounds, and a method for using the pharmaceutical composition in the treatment of HCV infection.

PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE

Disclosed are pyrazolo[3,4-b]pyridine and pyrrolo[2,3-b]pyridine inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combin